Review into Nottingham NHS maternity failings launches

Families are urged to take part in the review being conducted by influential midwife Donna Ockenden.

Share Button

Hakeem Hussain: ‘Horrendous’ lack of help for asthma death boy

A review finds fault with various agencies over their handling of seven-year-old Hakeem Hussain.

Share Button

Energy crisis: Leeds NHS trust expects £2m monthly price hike

Hospital trusts in Leeds and Sheffield predict a huge jump in energy bills.

Share Button

Drug combo therapy in mice blocks drug resistance, halts tumor growth

An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a study in mice from researchers at Washington University School of Medicine in St. Louis, Grenoble Alpes University in Grenoble, France, and The University of Texas MD Anderson Cancer Center in Houston.

One of the drugs, cyclophosphamide, is an outdated chemotherapy drug once used to treat small cell lung cancer. It was displaced in favor of platinum-based drugs in the 1980s. Both kinds of drugs work at first but falter after a few months as the cancer develops resistance. Platinum-based drugs became the standard of care mainly because they cause lesser side effects, but they have not substantially improved prognosis. Today, the typical patient survives less than a year and a half after diagnosis.

In this study, however, researchers showed that small cell lung cancer cells resist cyclophosphamide by activating a specific repair process, and demonstrated that throwing a wrench into the repair process makes the drug much more effective, at least in mice. The findings, available online in Cancer Discovery, suggest a pathway to better therapies for one of the least treatable forms of cancer.

“Small cell lung cancer has one treatment option — platinum-based chemotherapy — and that adds maybe two to six months of life,” said co-senior author Nima Mosammaparast, MD, PhD, an associate professor of pathology & immunology and of medicine at Washington University, and a researcher at Siteman Cancer Centerat Barnes-Jewish Hospital and Washington University School of Medicine. “The problem is that these tumors respond to treatment initially, but then they come back. This has not changed for 30 years. These tumors are just massively resistant to just about everything. So what this study shows is that we can actually combine a new target with an old drug to reduce resistance and potentially make the treatment much better and give these patients a much better chance.”

The study came together fortuitously. Co-senior author Nicolas Reynoird, PhD, a professor at Grenoble Alpes University, studies how internal signaling within cells — and deregulation of such signaling — can lead to cancer progression and drug resistance. A few years ago, his team discovered that a protein called RNF113A may play a role in small cell lung cancer, but the researchers could not determine what the protein does. Meanwhile, Mosammaparast was studying how cells repair injured DNA. In 2017, he published a paper in the journal Nature describing how cancer cells repair a kind of DNA damage known as alkylation damage, the kind caused by cyclophosphamide. The paper noted that RNF113A plays a role in the process. Reynoird essentially cold-called Mosammaparast, and the two teamed up — along with co-senior author Pawel K. Mazur, PhD, an associate professor of experimental radiation oncology at MD Anderson and a longstanding collaborator of Reynoird’s — to investigate how small cell lung cancer cells resist alkylation damage, and whether it’s possible to magnify the effects of alkylating chemotherapy drugs such as cyclophosphamide by interfering with that resistance.

The team discovered that RNF113A is regulated by a protein called SMYD3 that is highly expressed in small cell lung cancer and some other cancers. High levels of SMYD3 are associated with more invasive disease, increased resistance to alkylating chemotherapy and worse prognosis. Healthy lung tissue has very little SMYD3, which led the researchers to think that knocking it down might target cancerous cells while sparing healthy ones.

So they tried it. The researchers created mouse models of human disease by grafting cancerous cells from two people with small cell lung cancer onto separate groups of mice. One set of cells came from a patient who had not yet been treated, so the cells had not had a chance to develop resistance. The other came from a patient who had been treated with and become resistant to standard platinum-based therapy.

All of the mice grew tumors. When the tumors were big enough, the researchers treated the mice with an inhibitor of SMYD3, cyclophosphamide, both or an inactive solution. Inhibiting SMYD3 alone modestly slowed down the growth of the tumors. Cyclophosphamide initially halted the growth of tumors from both patients, but the tumors started to grow again after about two weeks, indicating that they had developed resistance. However, the combination of the two drugs stopped the tumors in their tracks. They did not restart growing for the duration of the experiment.

“We’re talking to a number of other groups about starting a phase 1 clinical trial as soon as possible,” Mosammaparast said. “One of the challenges we will face is convincing doctors to go back to an old drug. But the nice thing about this strategy is that it may work where current therapies have failed. This treatment worked just as well against the tumor from the patient who had already relapsed on platinum-based therapy as it did against the untreated patient. People with small cell lung cancer are in desperate need of better treatments, and I’m very excited about the possibilities here.”

Story Source:

Materials provided by Washington University School of Medicine. Original written by Tamara Bhandari. Note: Content may be edited for style and length.

Share Button

Scientists discover compound found in trees has potential to kill drug-resistant bacteria

Researchers have found a naturally occurring compound, known as hydroquinine, has bacterial killing activity against several microorganisms.

Antimicrobial resistance has become one of the greatest threats to public health globally. It occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making it difficult to treat infections. Because of this, there is a pressing need for the development of new antimicrobial drugs to combat infections.

A new study by scientists from the University of Portsmouth and Naresuan and Pibulsongkram Rajabhat Universities in Thailand explored whether hydroquinine, which is found in the bark of some trees, could inhibit any bacterial strains. Hydroquinine is already known to be an effective agent against malaria in humans, but until now there has been little investigation into its drug-resistant properties.

The findings, published in the Tropical Medicine and Infectious Disease journal, suggest the antimicrobial properties of the organic compound make it a potential candidate for future clinical investigation.

Dr Robert Baldock from the School of Pharmacy and Biomedical Sciences at the University of Portsmouth, said: “Using bacterial killing experiments, we found that hydroquinine was able to kill several microorganisms including the common multidrug-resistant pathogen pseudomonas aeruginosa.

“Characteristically, we also discovered that one of the main mechanisms used by these bacteria to escape killing activity of the drug was upregulated with treatment — indicating a robust response from the bacteria.

“By studying this compound further, our hope is that it may in future offer another line of treatment in combatting bacterial infections.”

Drug-resistant bacteria occur in more than 2.8 million infections and are responsible for 35,000 deaths per year. Common antibiotic-resistant “superbugs” cause diseases including sepsis, urinary tract infections, and pneumonia. Statistics show bloodstream infections with the bacteria — P. aeruginosa are associated with high mortality rates of between 30 and 50%.

The study recommends further investigation into the antimicrobial resistance properties and side effects of hydroquinine.

Dr Jirapas Jongjitwimol from the Department of Medical Technology at Naresuan University added: “Our future research aims to uncover the molecular target of hydroquinine. This would help our understanding of how the compound works against pathogenic bacteria and how it could potentially be used in a clinical setting.”

Story Source:

Materials provided by University of Portsmouth. Note: Content may be edited for style and length.

Share Button

Covid: Pregnant women targeted with false vaccine claims

Posts shared by thousands across social media wrongly suggested government advice had changed.

Share Button

Covid inquiry starts to examine Boris Johnson’s pandemic decisions

Boris Johnson, Matt Hancock and Dominic Cummings are likely to appear in hearings next summer.

Share Button

What you know changes how you see things

Researchers at the George Washington University have gained important insight into how the human brain processes an object in the visual system and where in the brain this processing takes place. Their study, “Mugs and Plants: Object Semantic Knowledge Alters Perceptual Processing with Behavioral Ramifications,” shows people perceive objects differently depending on their prior knowledge and experience with that object.

The findings could have important implications in applied settings such as medical displays, cognitive assistants, and product and environmental design, according to the researchers.

“Since the way we perceive objects determines how we interact with them, it is important to visually process them quickly and with high detail” Sarah Shomstein, a professor of cognitive neuroscience at GW said. “However, the way our eyes perceive and process an object can be different depending on what we know about this object. Our study shows, for the first time, that if we recognize an object as a tool, we perceive it faster but with less detail. If we recognize an object as a non-tool, we perceive it slower but with higher detail.”

To determine how the human brain processes an object visually, Shomstein and Dick Dubbelde, a recent PhD graduate at GW and co-author on the study, showed participants several images of objects that can be easily manipulated by hand such as a coffee mug, snow shovel or screwdriver, and several images of objects that are infrequently manipulated by hand, such as a potted plant, a picture frame or a fire hydrant. For half of the experiment, a small gap could be cut out of the bottom of each object. For the other half of the experiment, the objects could flicker on the screen. The team asked participants to report the presence or absence of a gap or the flicker, which helped the researchers figure out the speed and detail of object processing, and also which regions of the brain were being used to process the object.

Researchers found that objects usually manipulated by your hands are perceived faster than non-manipulable objects, making it easier to see the flickering. Alternatively, objects that we usually do not manipulate are perceived with greater detail than manipulable objects, making it easier to see the small gaps.

“The differences in perception between ‘mugs’ and ‘plants’ in both speed and detail of perception means that these objects are sorted by the visual system for processing in different brain regions,” Dubbelde said. “In other words, your knowledge of the object’s purpose actually determines where in the brain object processing will occur and how well you will perceive it.”

The study also showed that if you interfere with object recognition by making it harder to recognize an object as either manipulable or not manipulable — for example, by turning it upside down — then the differences in the speed and detail perception of the objects disappear.

Shomstein and Dubbelde note that this study could possibly explain individual differences in object perception and underscores that what you know and what your personal experience is with any particular object has direct consequences for perception.

The National Science Foundation (BCS-1921415 and BCS-2022572) supported this work.

Story Source:

Materials provided by George Washington University. Note: Content may be edited for style and length.

Share Button

Elton John Remembers Princess Diana On 25th Anniversary Of Her Death

Sir Elton John has paid tribute to Diana, Princess of Wales, on the 25th anniversary of her death.

The singer was close friends with the princess prior to her death in August 1997, when she was killed in a car crash in Paris.

Elton reworked his hit song Candle In The Wind to perform at her funeral, which was subsequently released and became the biggest-selling single in UK chart history up to that date.

On Wednesday, Elton posted a picture of himself with Diana on Instagram.

“You will always be missed,” he wrote.

The pair’s friendship is said to have begun after Elton was reportedly hired to perform at Prince Andrew’s 21st birthday celebrations in 1981.

They were said to have bonded while dancing to the Charleston together on the dancefloor.

Elton performing a rewritten version of his song Candle In The Wind as a tribute to Diana, Princess of Wales, at her funeral
Elton performing a rewritten version of his song Candle In The Wind as a tribute to Diana, Princess of Wales, at her funeral

PA Images via Getty Images

Elton and Diana went on to work together helping to raise awareness of AIDS.

In 2018, Elton praised Diana for helping to smash stigma surrounding the disease when she publicly shook hands with a patient in 1987.

“One simple handshake, one gesture showed the world the desperate need for humanity for people living with AIDS,” he said.

“She knew the disease could not be communicated by hand. Her gesture meant nobody should be left behind. She did not distinguish between ‘us’ and ‘them’.”

Speaking at a Princess of Wales memorial lecture, he added: “I like to think she would be proud and astonished if she could see the progress that has been made since she left us.”

Elton has regularly supported Diana’s sons William and Harry over the years and attended both their royal weddings alongside his husband, David Furnish.

Share Button

‘It Is A Catastrophe!’: Martin Lewis And Edwina Currie In Spat Over Energy Bill Crisis

Martin Lewis took on former Conservative minister Edwina Currie on Twitter on Wednesday, after she called out his approach to the energy crisis.

Lewis, a consumer journalist known as the Money Saving Expert, has repeatedly shared his exasperation towards the government as the energy price cap is set to hurtle towards £3,549 come October 1.

He called on either Liz Truss or Rishi Sunak, the two remaining contenders left in the race to be the next prime minister, to sit down in an ITV special once they take office to field questions over the cost of living crisis.

His tweet quickly went viral and grabbed Currie’s attention, a former Tory MP who briefly served as a junior health minister under John Major. She lost her seat in 1997′s general election.

Currie is now known for being an outspoken public figure, a media personality and an author – and she had plenty to say about Lewis’ plea to the government on Wednesday.

She tweeted: “I would like you, Martin, to stop using words like ‘catastrophe’, and instead advise people take sensible steps to reduce the effect on their families and businesses.

“And stop pretending that governments can do everything. They can’t.”

He then responded: “It is a catastrophe Edwina!

“While there are steps people can take to help themselves (I explain them in today’s email mse.me/latesttip), energy bills by Jan will cost on average over half the full state pension and bigger proportion of basic UC [Universal credit].

“No sensible steps cover that!”

Several hours later, Lewis also put together a Twitter poll which asked: “Do you think it is fair to call the coming winter energy and cost of living price hikes a ‘catastrophe’?

“Votes split by whether you traditionally vote for Conservatives )even if not right now) or not. To see if view correlates with political stance.”

He tweeted summarising his findings (long before the poll officially closed) by pointing out that of 15,000 votes, 90% of Conservative voters and 95% of non-Tory voters agreed that it was fair to call the crisis a “catastrophe”.

However, Lewis did note that this was a Twitter poll, and therefore does not fairly represent the population.

Currie also replied to Lewis directly, saying: “Emphasise the help. Include local authorities, as in Germany.

“Give people something they can do…not just wringing their hands. The more those who can reduce usage, the easier it gets for those who can’t. Every little helps.

“And no, governments cannot do everything.”

It’s worth noting that Germany has unveiled a long-term strategy to cut energy costs, including insulating old buildings, while also offering one-off payments for workers who pay income tax.

Meanwhile, Downing Street has been called a “zombie government” (by Lewis) and criticised over its inaction for weeks now – especially as the cost of living package offered in May is now nowhere near enough to meet the current needs of the crisis.

Share Button